Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn’s Disease

Zhigang Wang(Dalian Medical University), Erwin Dreesen(KU Leuven), Séverine Vermeire(KU Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), João Sabino(KU Leuven), Paul Declerck(KU Leuven), Yannick Hoffert(KU Leuven), Wei Zhang(Tianjin Medical University Cancer Institute and Hospital), David Laharie(Université de Bordeaux), G D’Haens(Amsterdam University Medical Centers), Wannee Kantasiripitak(Certara (United States))
Clinical Gastroenterology and Hepatology
September 7, 2025
10.1016/j.cgh.2025.08.030
Cited by 3

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k